203 related articles for article (PubMed ID: 31405345)
1. Descriptive Analysis of Long- and Intermediate-Acting Insulin and Key Safety Outcomes in Adults with Type 2 Diabetes Mellitus.
Kent DJ; McMahill-Walraven CN; Panozzo CA; Pawloski PA; Haynes K; Marshall J; Brown J; Eichelberger B; Lockhart CM
J Manag Care Spec Pharm; 2019 Nov; 25(11):1162-1171. PubMed ID: 31405345
[TBL] [Abstract][Full Text] [Related]
2. Harnessing the Biologics and Biosimilars Collective Intelligence Consortium to Evaluate Patterns of Care.
McMahill-Walraven CN; Kent DJ; Panozzo CA; Pawloski PA; Haynes K; Marshall J; Brown J; Eichelberger B; Lockhart CM
J Manag Care Spec Pharm; 2019 Nov; 25(11):1156-1161. PubMed ID: 31397619
[TBL] [Abstract][Full Text] [Related]
3. Incidence of Serious Infections and Design of Utilization and Safety Studies for Biologic and Biosimilar Surveillance.
Zhang J; Sridhar G; Barr CE; Eichelberger B; Lockhart CM; Marshall J; Clewell J; Accortt NA; Curtis JR; Holmes C; McMahill-Walraven CN; Brown JS; Haynes K
J Manag Care Spec Pharm; 2020 Apr; 26(4):417-490. PubMed ID: 32223608
[TBL] [Abstract][Full Text] [Related]
4. A bridge to insulin pump therapy: twice-daily regimen with NPH and detemir insulins during initial treatment of youth with type 1 diabetes mellitus.
Cengiz E; Sherr JL; Erkin-Cakmak A; Weinzimer SA; Burke EN; Sikes KA; Urban AD; Tamborlane WV
Endocr Pract; 2011; 17(6):862-6. PubMed ID: 21550949
[TBL] [Abstract][Full Text] [Related]
5. Assessment of basal insulin adherence using 2 methodologies among Texas Medicaid enrollees with type 2 diabetes.
Zhang H; Barner JC; Moczygemba LR; Rascati KL
J Manag Care Spec Pharm; 2020 Nov; 26(11):1434-1444. PubMed ID: 33119450
[No Abstract] [Full Text] [Related]
6. Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Basal Insulin and Basal-Bolus Therapy in Patients with Type 2 Diabetes Based on Attainment of Clinically Relevant Treatment Targets.
Cannon AJ; Bargiota A; Billings L; Hunt B; Leiter LA; Malkin S; Mocarski M; Ranthe MF; Schiffman A; Doshi A
J Manag Care Spec Pharm; 2020 Feb; 26(2):143-153. PubMed ID: 31856636
[TBL] [Abstract][Full Text] [Related]
7. (Ultra-)long-acting insulin analogues for people with type 1 diabetes mellitus.
Hemmingsen B; Metzendorf MI; Richter B
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013498. PubMed ID: 33662147
[TBL] [Abstract][Full Text] [Related]
8. Systematic review and meta-analysis of randomized clinical trials comparing efficacy and safety outcomes of insulin glargine with NPH insulin, premixed insulin preparations or with insulin detemir in type 2 diabetes mellitus.
Rys P; Wojciechowski P; Rogoz-Sitek A; Niesyczyński G; Lis J; Syta A; Malecki MT
Acta Diabetol; 2015 Aug; 52(4):649-62. PubMed ID: 25585592
[TBL] [Abstract][Full Text] [Related]
9. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.
Semlitsch T; Engler J; Siebenhofer A; Jeitler K; Berghold A; Horvath K
Cochrane Database Syst Rev; 2020 Nov; 11(11):CD005613. PubMed ID: 33166419
[TBL] [Abstract][Full Text] [Related]
10. Influence of baseline glycemia on outcomes with insulin glargine use in patients uncontrolled on oral agents.
Banerji MA; Baron MA; Gao L; Blonde L
Postgrad Med; 2014 May; 126(3):111-25. PubMed ID: 24918797
[TBL] [Abstract][Full Text] [Related]
11. Treatment satisfaction, safety, and effectiveness of biosimilar insulin glargine is comparable in patients with type 2 diabetes mellitus after switching from insulin glargine or insulin degludec: a post-marketing safety study.
Taki K; Koyanagi M; Nagaoka S; Shingaki T
Curr Med Res Opin; 2020 Dec; 36(12):1975-1983. PubMed ID: 33030354
[TBL] [Abstract][Full Text] [Related]
12. Effect of V-Go Versus Multiple Daily Injections on Glycemic Control, Insulin Use, and Diabetes Medication Costs Among Individuals with Type 2 Diabetes Mellitus.
Raval AD; Nguyen MH; Zhou S; Grabner M; Barron J; Quimbo R
J Manag Care Spec Pharm; 2019 Oct; 25(10):1111-1123. PubMed ID: 31556817
[TBL] [Abstract][Full Text] [Related]
13. Reduced risk of hypoglycemia with once-daily glargine versus twice-daily NPH and number needed to harm with NPH to demonstrate the risk of one additional hypoglycemic event in type 2 diabetes: Evidence from a long-term controlled trial.
Rosenstock J; Fonseca V; Schinzel S; Dain MP; Mullins P; Riddle M
J Diabetes Complications; 2014; 28(5):742-9. PubMed ID: 24856612
[TBL] [Abstract][Full Text] [Related]
14. Negative binomial meta-regression analysis of combined glycosylated hemoglobin and hypoglycemia outcomes across eleven Phase III and IV studies of insulin glargine compared with neutral protamine Hagedorn insulin in type 1 and type 2 diabetes mellitus.
Mullins P; Sharplin P; Yki-Jarvinen H; Riddle MC; Haring HU
Clin Ther; 2007 Aug; 29(8):1607-19. PubMed ID: 17919543
[TBL] [Abstract][Full Text] [Related]
15. Slow Titration and Delayed Intensification of Basal Insulin Among Patients with Type 2 Diabetes.
Mocarski M; Yeaw J; Divino V; DeKoven M; Guerrero G; Langer J; Thorsted BL
J Manag Care Spec Pharm; 2018 Apr; 24(4):390-400. PubMed ID: 29406841
[TBL] [Abstract][Full Text] [Related]
16. A real-world study of patients with type 2 diabetes initiating basal insulins via disposable pens.
Xie L; Wei W; Pan C; Du J; Baser O
Adv Ther; 2011 Nov; 28(11):1000-11. PubMed ID: 22038703
[TBL] [Abstract][Full Text] [Related]
17. Modulation of insulin dose titration using a hypoglycaemia-sensitive algorithm: insulin glargine versus neutral protamine Hagedorn insulin in insulin-naïve people with type 2 diabetes.
Home PD; Bolli GB; Mathieu C; Deerochanawong C; Landgraf W; Candelas C; Pilorget V; Dain MP; Riddle MC
Diabetes Obes Metab; 2015 Jan; 17(1):15-22. PubMed ID: 24957785
[TBL] [Abstract][Full Text] [Related]
18. Improved glycemic control with insulin glargine versus pioglitazone as add-on therapy to sulfonylurea or metformin in patients with uncontrolled type 2 diabetes mellitus.
Meneghini LF; Traylor L; Schwartz SL
Endocr Pract; 2010; 16(4):588-99. PubMed ID: 20350924
[TBL] [Abstract][Full Text] [Related]
19. Real-World Analysis of Long-Acting and NPH-Containing Insulins on Glycemic Control.
Hale G; Marcellus V; Benny T; Moreau C; Rosario E; Perez A
Sr Care Pharm; 2024 Jan; 39(1):42-49. PubMed ID: 38160236
[No Abstract] [Full Text] [Related]
20. Association of Initiation of Basal Insulin Analogs vs Neutral Protamine Hagedorn Insulin With Hypoglycemia-Related Emergency Department Visits or Hospital Admissions and With Glycemic Control in Patients With Type 2 Diabetes.
Lipska KJ; Parker MM; Moffet HH; Huang ES; Karter AJ
JAMA; 2018 Jul; 320(1):53-62. PubMed ID: 29936529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]